US FDA grants priority review to sonrotoclax in relapsed or refractory MCL
The US Food and Drug Administration accepted and granted priority review to a new drug application for sonrotoclax, a next-generation BCL2 inhibitor, for
Lymphoma
Mantle Cell Lymphoma
News
Cellular Therapy
Lymphoma
News
US FDA approves liso-cel in relapsed or refractory MZL
The US Food and Drug Administration has approved lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or
Past Sessions
Community Oncology
News
Building partnerships between community and academic centers
Krish Patel presents at 1:15 pm CST on April 15, 2026, on building partnerships between community and academic centers.
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
News
FDA grants traditional approval to pirtobrutinib in relapsed or refractory CLL/SLL
The United States Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with
Past Sessions
Community Oncology
Dr. Jeffrey Matous on managing access to novel agents in the community setting
Held on March 18, 2026, from 12:30–1:00 PM CST with Jeffrey Matous presenting "Managing Access to Novel Agents in the Community Setting."
Past Sessions
Manali Kamdar on Expanding access to CAR T-cell therapy outside academic centers
Manali Kamdar, MD, will present at 4:30–5 pm on January 20, 2026, on “Expanding access to CAR T-cell therapy outside academic centers.”
Leukemia News
SOHO 2025
News
Video Interviews
Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL
In this panel discussion at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at
Multiple Myeloma
News
FDA adds enterocolitis risk warning to approved CAR-T cell therapy
The US Food and Drug Administration (FDA) approved updates to the prescribing information for ciltacabtagene autoleucel (CARVYKTI). The agency added a boxed warning
Cellular Therapy
Lymphoma
Mantle Cell Lymphoma
Liso-cel receives expanded approval in R/R MCL by European Commission
The European Commission expanded approval of the CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi®) in patients with relapsed or refractory
Multiple Myeloma
Video Interviews
Dr. Abdallah on blenrep combo approval in relapsed myeloma
In this video interview with SOHO Insider Al-Ola A. Abdallah, MD, associate professor and director of the Plasma Cell Disorder program at the